logo
ProjectEnded

anti-Bacterial Innovative Vaccine Training Network.

Sector: Hospital • Location: Ireland, Italy, United Kingdom, Spain, Germany, Switzerland, Hungary, Belgium

Source: EU Funding & Tenders Portal

BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative minds

Status
Closed
Sector
Hospital, Commercial, Rail, Education, Government
Location
Ireland, Italy, United Kingdom, Spain, Germany, Switzerland, Hungary, Belgium
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about anti-Bacterial Innovative Vaccine Training Network.

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “anti-Bacterial Innovative Vaccine Training Network.” is an infrastructure initiative in the Hospital sector, located in Ireland, Italy, United Kingdom, Spain, Germany, Switzerland, Hungary, Belgium. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative mindsets. BactiVax will train ESRs in a broad range of transferable skills enabling them to thrive in careers in vaccine research within academia and/or industry through discovery, development, and delivery of innovative therapeutic and prophylactic vaccines. The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to: 1) Identify novel, protective vaccine antigens against target pathogens; 2) Optimise the host response to vaccines; 3) Optimise vaccine delivery; 4) Lead on vaccine advocacy. BactiVax includes 2 SME beneficiaries, a multinational vaccine company and 4 SMEs as partners all of whom are involved in training, entrepreneurship, commercial vaccine development and vaccine antigen processing. All ESRs will have secondments in non-academic environment to enhance their exposure to the commercial. Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines

Location

Country

Ireland, Italy, United Kingdom, Spain, Germany, Switzerland, Hungary, Belgium

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Commercial, Rail, Education, Government

Article published date

2026-02-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project